| Literature DB >> 28814894 |
C Horn-Hofmann1, D Wolf1, S Wolff1, M Heesen2, K Knippenberg-Bigge3, P M Lang3, S Lautenbacher1.
Abstract
BACKGROUND: Empirical evidence suggests that affective responses to pain are changed in chronic pain. The investigation of startle responses to pain might contribute to clarifying whether such alterations also expand to motivational defensive reactions. We aimed at comparing startle responses to tonic heat pain with high threat (HT) or low threat (LT) in patients with chronic musculoskeletal pain and controls. As pain-related anxiety and catastrophizing are typically elevated in chronic pain, we expected to find stronger startle responses in patients specifically under experimental HT.Entities:
Keywords: anxiety; catastrophizing; defensive motivation; experimental pain; musculoskeletal pain; startle reflex; threat induction
Year: 2017 PMID: 28814894 PMCID: PMC5546785 DOI: 10.2147/JPR.S136416
Source DB: PubMed Journal: J Pain Res ISSN: 1178-7090 Impact factor: 3.133
Predominant pain sites in patients with chronic pain (n = 19)
| Diagnosis | Total | Percent |
|---|---|---|
| Chronic back pain, thereof | 10 | 53 |
| Neck pain | 1 | |
| Upper back pain | 1 | |
| Low back pain | 6 | |
| Neck pain and low back pain | 2 | |
| Chronic back pain and fibromyalgia, thereof | 1 | 5 |
| Low back pain and fibromyalgia | 1 | |
| Chronic back pain and headache, thereof | 3 | 16 |
| Neck pain and migraine | 1 | |
| Neck pain, low back pain, and headache (not specified) | 1 | |
| Neck pain, low back pain, TTH, and migraine | 1 | |
| Chronic back pain, fibromyalgia, and headache, thereof | 2 | 10.5 |
| Neck pain, fibromyalgia, and TTH | 1 | |
| Neck pain, low back pain, fibromyalgia, and migraine | 1 | |
| Fibromyalgia | 2 | 10.5 |
| Fibromyalgia and headache, thereof | 1 | 5 |
| Fibromyalgia, TTH, and migraine | 1 |
Note: Diagnoses made by medical doctor trained in anesthesiology and pain therapy.
Abbreviation: TTH, tension-type headache.
Consumption of analgesics and antidepressants in the chronic pain patients (n = 19)
| Medication | Total | Percent |
|---|---|---|
| Analgesics | 17 | 89 |
| On demand, thereof | 4 | |
| Nonsteroidal anti-inflammatories | 1 | |
| Nonopioid analgesics | 0 | |
| Nonsteroidal anti-inflammatories and nonopioid analgesics | 2 | |
| Nonsteroidal anti-inflammatories and opioid analgesics | 1 | |
| On demand in combination with antidepressants, thereof | 1 | |
| Nonsteroidal anti-inflammatories | 1 | |
| As prescribed, thereof | 4 | |
| Nonsteroidal anti-inflammatories | 2 | |
| Nonsteroidal anti-inflammatories and opioid analgesics | 1 | |
| Nonsteroidal anti-inflammatories, nonopioid analgesics, and opioid analgesics | 1 | |
| As prescribed in combination with antidepressants, thereof | 8 | |
| Nonsteroidal anti-inflammatories | 4 | |
| Nonopioid analgesics | 2 | |
| Nonsteroidal anti-inflammatories and nonopioid analgesics | 1 | |
| Nonopioid analgesics and opioid analgesics | 1 | |
| Antidepressants | 2 | 11 |
Note: Analgesics consumed as prescribed and were taken at least once a day.
Figure 1Trial design of both the threat conditions (low threat and high threat conditions).
Descriptive statistics of questionnaire scores for patients and controls in our questionnaire
| M (SD) | M (SD) | |
|---|---|---|
| PCS | 29.79 (9.32) | 14.53 (9.35) |
| PASS | 109.16 (35.48) | 58.89 (30.16) |
| PVAQ | 50.37 (9.54) | 35.63 (10.02) |
| ASI | 23.53 (13.44) | 11.47 (5.72) |
Abbreviations: PVAQ, Pain Vigilance and Awareness Questionnaire; PASS, Pain Anxiety Symptom Scale; PCS, Pain Catastrophizing Scale; ASI, Anxiety Sensitivity Index.
Descriptive statistics of startle amplitude (μV) for patients and controls for each trial block (1–4) in both the threat conditions (high threat and low threat)
| Trial block | M (SD) | M (SD) | |
|---|---|---|---|
| High threat condition | Block 1 (Trials 1–3) | 19.33 (24.10) | 28.71 (48.83) |
| Block 2 (Trials 4–6) | 18.37 (32.66) | 25.56 (45.53) | |
| Block 3 (Trials 7–9) | 18.08 (26.45) | 25.10 (46.00) | |
| Block 4 (Trials 10–12) | 12.25 (13.91) | 21.63 (36.25) | |
| Low threat condition | Block 1 (Trials 1–3) | 11.47 (14.23) | 19.00 (23.06) |
| Block 2 (Trials 4–6) | 12.30 (14.23) | 16.85 (20.68) | |
| Block 3 (Trials 7–9) | 11.44 (17.21) | 15.61 (24.56) | |
| Block 4 (Trials 10–12) | 12.98 (20.30) | 18.35 (32.57) |
Figure 2Startle amplitude (M + SE) in the two threat conditions for both the sequences (high threat–low threat and low threat–high threat) and both the groups (patients and controls).
Notes: p ≤ 0.05 (exact significance: see text - 0.025 for HT, 0.050 for LT).
Abbreviations: M, mean; SE, standard error; HT, high threat,; LT, low threat.
Results of repeated measurement ANOVAs (condition × sequence of conditions) for temperature and startle noise ratings (N = 40, patients and controls combined)
| Factor | η2 | |||
|---|---|---|---|---|
| Temperature valence ratings | Condition | 3.403 | 0.073 | 0.086 |
| Sequence of conditions | 1.462 | 0.234 | 0.039 | |
| Condition × sequence of conditions | ||||
| Temperature arousal ratings | Condition | 2.082 | 0.158 | 0.055 |
| Sequence of conditions | 0.321 | 0.574 | 0.009 | |
| Condition × sequence of conditions | 1.229 | 0.275 | 0.033 | |
| Startle noise ratings | Condition | 2.099 | 0.156 | 0.057 |
| Sequence of conditions | 1.559 | 0.220 | 0.043 | |
| Condition × sequence of conditions | 0.793 | 0.379 | 0.022 |
Note: Bold figures indicate significant (p < 0.05).
Abbreviation: ANOVA, analysis of variance.